Essayer OR - Gratuit
Targeted Transformation of Diabetes Care in India
Bio Spectrum
|BioSpectrum India Nov 2024
According to the International Diabetes Federation (IDF) about 63 per cent of people with diabetes say that the fear of developing diabetes-related complications affects their well-being. And around 28 per cent of people with diabetes find it hard to remain positive in relation to their condition. Hence the theme for this year's World Diabetes Day (WDD) 2024-26 observed on November 14, the world's largest diabetes awareness campaign reaching a global audience of over 1 billion people in over 160 countries, is Diabetes and well-being. Let's look at ways to reduce or reverse diabetes in India.
The Indian Council of Medical Research– India Diabetes (ICMR-INDIAB) study published in 2023 reported that the overall weighted prevalence of diabetes in India was 11·4 per cent, accounting for 101 million people. The study findings also reported an alarming increase in non-communicable diseases (NCDs) such as prediabetes, hypertension, and obesity. Hence, there is a rising need to holistically manage the rising diabetes prevalence by improving awareness, diet, lifestyle, screening, treatment and monitoring practices in India.
Public and Private Campaigns for Improving Awareness
A study of the National Family Health Survey of India (NFHS), 2019–2021 reported that diabetes awareness varied from 14.4 per cent to 54.4 per cent. Not surprisingly, the less educated and poorer sections of the society had lower diabetes awareness. Thus, considering the rising prevalence of the disease, there is a need to improve diabetes awareness in India. Several public and private initiatives are looking to address this concern.
However, it is important to ensure that the awareness campaigns have wider outreach.
For instance, mDiabetes, launched in collaboration with the Ministry of Health and Family Welfare, India and the World Health Organization (WHO) aims to provide basic diabetes information to users who dial a missed call to a number. This is likely to ensure a wide outreach as even rural Indian sectors have good mobile connectivity in India. In 2021, the Research Society for the Study of Diabetes in India (RSSDI) launched the Defeat Diabetes Campaign to reach out to over 100 million people in 100 days to ‘test, track and treat’ diabetes. The campaign was successful and managed to screen over 106 million people in over 10,000 locations in India. There is a need to continue such targeted campaigns with well-defined outcomes and timelines.
Cette histoire est tirée de l'édition BioSpectrum India Nov 2024 de Bio Spectrum.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Bio Spectrum
Bio Spectrum
MAHE teams up with OpenAI to integrate AI to enhance outcomes
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.
1 min
April 2026
Bio Spectrum
Jubilant Bhartia Foundation & McGill University to launch CoE in AI education
The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.
1 min
April 2026
Bio Spectrum
Heeding Auditory Warning Signs
By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).
2 mins
April 2026
Bio Spectrum
Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer
Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).
1 min
April 2026
Bio Spectrum
Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer
Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.
1 min
April 2026
Bio Spectrum
Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow
Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers
1 min
April 2026
Bio Spectrum
UK deploys new bone scanners to help prevent fractures
Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.
1 min
April 2026
Bio Spectrum
Cytiva expands Fast Trak process development and validation services facility in India
Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.
1 min
April 2026
Bio Spectrum
ΑΙ TAKES INDIAN PHARMA REINS
The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.
10 mins
April 2026
Bio Spectrum
NIH halts arm of clinical trial evaluating potential stroke treatment
The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).
1 min
April 2026
Listen
Translate
Change font size
